A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

NCT01859026 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Non-Small Cell Lung Cancer

Interventions

DRUG: MEK162
DRUG: Erlotinib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]